Teal Health has raised $22 million in a Series A round to scale its FDA-authorized self-collection device for at-home HPV cervical cancer screening. The round, which brings the company’s total funding to $45 million, was led by .406 Ventures with participation from existing backers Emerson Collective (managed by Yosemite), Forerunner, Labcorp, and Serena Ventures, as well as new investor MPower Labs.
With one in three women not up to date on cervical screening, Teal Health launched to make screening more accessible. Its FDA-authorized Teal Wand allows patients to collect samples at home and mail them to a lab for analysis.
“We designed Teal for all women, whether they are behind on their screening or coming due. Screening is just too difficult today, whether that is finding an appointment, the time in your day to attend, or the physical discomfort. Women need an accurate, trusted alternative that makes it easy to screen,” said Kara Egan, Teal Health Co-Founder and CEO.
Teal has screened thousands of women and recently launched a study with UC Davis to evaluate the device’s use in clinical workflows.
The latest funding will support Teal’s efforts to meet growing demand from patients and providers. The company also expects the Teal Wand to receive broader insurance coverage starting in 2027, following updated federal guidelines on cervical cancer screening via self-collection.
“Patients are demanding more convenient ways to access healthcare, and Teal has proven that convenience doesn’t have to come at the expense of accuracy,” said Kathryn Taylor Reddy, Partner at .406 Ventures. “With insurance coverage expanding in 2027, Teal Health is positioned to transform how millions of women receive essential preventive healthcare.”
